J 2018

Bioaccessibility of PBDEs present in indoor dust: A novel dialysis membrane method with a Tenax TA® absorption sink

KADEMOGLOU, Aikaterini, Adrian C. WILLIAMS a Chris D. COLLINS

Základní údaje

Originální název

Bioaccessibility of PBDEs present in indoor dust: A novel dialysis membrane method with a Tenax TA® absorption sink

Autoři

KADEMOGLOU, Aikaterini (300 Řecko, garant, domácí), Adrian C. WILLIAMS a Chris D. COLLINS

Vydání

Science of The Total Environment, Elsevier B.V. 2018, 0048-9697

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10511 Environmental sciences

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.589

Kód RIV

RIV/00216224:14310/18:00124574

Organizační jednotka

Přírodovědecká fakulta

UT WoS

000424196800001

Klíčová slova anglicky

Bioaccessibility; Tenax TA®; Dialysis membrane; PBDEs; Indoor dust

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 11. 5. 2022 15:09, Mgr. Marie Šípková, DiS.

Anotace

V originále

Human uptake of flame retardants (FRs) such as polybrominated diphenyl ethers (PBDEs) via indoor dust ingestion is commonly considered as 100% bioaccessible, leading to potential risk overestimation. Here, we present a novel in vitro colon-extended physiologically-based extraction test (CE-PBET) with Tenax TA® as an absorptive “sink” capable to enhance PBDE gut bioaccessibility. A cellulose-based dialysis membrane (MW cut-off 3.5 kDa) with high pH and temperature tolerance was used to encapsulate Tenax TA®, facilitating efficient physical separation between the absorbent and the dust, while minimizing re-absorption of the ingested PBDEs to the dust particles. As a proof of concept, PBDE-spiked indoor dust samples (n = 3) were tested under four different conditions; without any Tenax TA® addition (control) and with three different Tenax TA® loadings (i.e. 0.25, 0.5 or 0.75 g). Our results show that in order to maintain a constant sorptive gradient for the low MW PBDEs, 0.5 g of Tenax TA® are required in CE-PBET. Tenax TA® inclusion (0.5 g) resulted in 40% gut bioaccessibility for BDE153 and BDE183, whereas greater bioaccessibility values were seen for less hydrophobic PBDEs such as BDE28 and BDE47 (~ 60%). When tested using SRM 2585 (n = 3), our new Tenax TA® method did not present any statistically significant effect (p > 0.05) between non-spiked and PBDE-spiked SRM 2585 treatments. Our study describes an efficient method where due to the sophisticated design, Tenax TA® recovery and subsequent bioaccessibility determination can be simply and reliably achieved.